Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single Intravenous Dose, Parallel Efficacy Study of Apimostinel With or Without Subsequent Automated Self-Association Training in Subjects With Major Depressive Disorder
Latest Information Update: 08 Feb 2025
At a glance
- Drugs Apimostinel (Primary) ; Apimostinel (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
Most Recent Events
- 03 Dec 2024 According to a Gate Neurosciences media release, company announced the initiation Phase 2 clinical study with the University of Pittsburgh (Pitt).
- 24 Oct 2024 Status changed from not yet recruiting to recruiting.
- 19 Sep 2024 Planned initiation date changed from 1 Sep 2024 to 1 Jan 2025.